Albuterol sulfate syrup
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Sulfate Syrup: Efficacy, Safety, and Pharmacokinetics
Introduction to Albuterol Sulfate Syrup
Albuterol sulfate is a beta-2-adrenergic bronchodilator commonly used to relieve bronchospasm in conditions such as asthma. It is available in various formulations, including tablets and syrup, each designed to cater to different patient needs and preferences 12.
Bioavailability and Pharmacokinetics of Albuterol Syrup
A study comparing the bioavailability of albuterol sulfate in syrup form with tablet formulations found that the syrup is rapidly absorbed, with maximum drug concentrations achieved between 1.8 to 2.0 hours post-administration. The bioavailability of the syrup was found to be equivalent to that of the tablet formulations, with similar areas under the plasma concentration-time curves (68-78 h X ng/mL) and elimination half-lives ranging from 4.8 to 5.5 hours .
Efficacy in Pediatric Asthma Treatment
Young Children (3-6 Years)
In a study involving asthmatic children aged 3 to 6 years, albuterol syrup was shown to be effective in improving pulmonary function and reducing asthma symptoms. The study reported significant improvements in FEV1 and FEF 25%-75% over three hours, along with better symptom scores and reduced need for additional medications. The syrup was well-tolerated, with only minor side effects such as increased heart rate and tremors .
Older Children (6-14 Years)
For children aged 6 to 14 years, albuterol syrup was found to be superior to tablet formulations in terms of efficacy. The syrup provided a longer duration of action, with its effects peaking at four hours and lasting up to six hours, compared to the tablet's peak at two hours and minimal effect after five hours. The study concluded that a 4 mg dose of albuterol syrup administered four times a day is the preferred regimen for this age group .
Safety and Tolerance
Albuterol syrup has been generally well-tolerated in pediatric populations. In studies involving both young and older children, no serious treatment-related adverse events were reported. Minor side effects such as increased heart rate and tremors were observed but were not clinically significant 35. Additionally, extended-release formulations of albuterol have been shown to be safe and effective for children aged 6 to 12 years, with no meaningful changes in vital signs or electrocardiograms .
Conclusion
Albuterol sulfate syrup is an effective and safe option for treating asthma in children. It offers rapid absorption and sustained efficacy, making it a preferred choice over tablet formulations for pediatric patients. The syrup formulation is particularly beneficial for young children and those who require a longer duration of action to manage their asthma symptoms effectively.
Sources and full results
Most relevant research papers on this topic
Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
Extended-release albuterol tablets (4 mg) effectively improved pulmonary function and asthmatic symptoms in children aged 6-12 years, with no serious treatment-related adverse events.
DOI
Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial.
Albuterol premedication significantly reduces the risk of perioperative respiratory adverse events in children undergoing tonsillectomy compared to placebo.
Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma.
HFA-134a albuterol sulfate provides bronchodilation comparable to CFC albuterol and has a similar safety profile in patients with asthma.
DOI